Vance Thompson Vision

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Vance Thompson Vision sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).

14 total trials 4 currently recruiting 9 completed later-stage tilt top decile by trial count

Vance Thompson Vision: 14 sponsored US clinical trials, 4 recruiting.

Vance Thompson Vision sponsors 14 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 9 completed. 4 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cataract, with 2 trials.

Top-decile sponsor footprint

Vance Thompson Vision ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

14 total, page 1 of 1

RECRUITING Phase 4

A Multicenter, Open-Label Study to Evaluate Perioperative Treatment of Dry Eye With Miebo® in Subjects Undergoing LASIK

NCT07650708
RECRUITING NA

Evaluating Crosslinked Hyaluronate Canalicular Gel for the Treatment of DED in Patients Undergoing Cataract Surgery

NCT07155057
RECRUITING Phase 4

Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK

NCT07155070
RECRUITING NA

Measuring Outcomes of LASIK and EVO-ICL in Matched Populations

NCT06700460
NOT YET RECRUITING NA

The Safety and Efficacy of Direct SLT in Pseudoexfoliation Glaucoma

NCT07401290
COMPLETED

Refractive and Visual Outcomes With the ARGOS Biometer In Eyes With a History of Refractive Surgery: ARGOS Study

NCT07129980
COMPLETED Early Phase 1

Evaluate the TetraLens, a Tetracaine Releasing Therapeutic Bandage Contact Lens in Patients Undergoing PRK Procedure

NCT06085352
COMPLETED Phase 4

In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery

NCT05023304
COMPLETED

Exploring Sedation Types During Cataract Surgery

NCT04725747
COMPLETED

Vivity Outcomes in Patients With Early Stage Glaucoma

NCT04670575
COMPLETED

Binocular Custom Vision Utilizing The Light Adjustable Lens (LAL)

NCT04533191
COMPLETED Phase 4

The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study

NCT04396990
COMPLETED

Analysis of Defocus Curve of Pre-Presbyopic and Emerging Presbyopic Patients

NCT04474782
COMPLETED NA

Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification

NCT04452279

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 4 4

Therapeutic Areas

Cataract 2
Pseudophakia 1
Dry Eye Disease (DED) 1
Presbyopia 1
Dry Eye 1
Myopia 1

Where Vance Thompson Vision enrollment is open (later-stage tilt)

4 recruiting of 14 indexed (29% open); 9 completed (64%).

Phase mix: 4 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Cataract (2 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Vance Thompson Vision: open-pipeline peers nationwide

Peers matched on 14 registered trials and 29% open enrollment, not the therapeutic-area sidebar.

Vance Thompson Vision sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30%40% Total trials Recruiting share Vance Thompson Vision3-C Institute for Social DevelopmentAbbott Medical OpticsAbbott RDx CardiometabolicAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA89bioAlabama Physical Therapy & AcupunctureAlloSourceAlnylam Pharmaceuticals
Vance Thompson Vision sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Vance Thompson Vision sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 14 trials (± recruiting share)

Sponsors near 29% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Vance Thompson Vision page

14 registered trials is a research-attention snapshot, not an endorsement of Vance Thompson Vision or any single study.

  • 4 of Vance Thompson Vision's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cataract is the condition Vance Thompson Vision studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cataract trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Vance Thompson Vision pipeline card: 14 registered trials from official public datasets.Report a data error.